BGMNasdaqPharmaceutical PreparationsFiscal year ends September 30
BGM Group Ltd.
Financials through fiscal 2025, year ended Sep 30, 2025Last filing: 20-F on Jul 21, 2026
$8.97+0.32 (+3.70%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
BGM Group Ltd. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Diversified Pharmaceutical and Allied Products | $23.59M | $25.10M | $46.47M | – | – | – | – | – | 62.2% | -6.0% |
| Insurance Business | $10.96M | – | – | – | – | – | – | – | 28.9% | – |
| AI Solutions | $3.36M | – | – | – | – | – | – | – | 8.9% | – |
| International markets | $0 | $0 | $0 | $0 | – | – | – | – | 0.0% | – |
| Fertilizer | – | $905.91K | $2.00M | $1.09M | $486.17K | $701.70K | $549.23K | $713.90K | – | – |
| Heparin products and Sausage casing | – | $2.23M | $15.32M | $23.46M | $23.16M | $16.73M | $15.40M | $16.23M | – | – |
| Oxytetracycline & Licorice products and TCMD | – | $21.96M | $29.15M | $40.31M | $33.45M | $32.60M | $30.15M | $33.43M | – | – |
By product or service
By region
From the segment and revenue-disaggregation notes of BGM's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.